Assessment of Intrapleural chemotherapy with cisplatin for treatment of malignant pleural effusio
- Conditions
- Malignant Pleural effusion.Secondary malignant neoplasm of pleura
- Registration Number
- IRCT2017053134256N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 21
Patients diagnosed with malignant pleural effusion who admitted from August 2016 till February 2017 in Masih Daneshvari hospital. Patients with Lung Carcinoma, Breast cancer and Mesothelium who their pleural effusion diagnosed and confirmed by Cytology results of pleurla fluid. Patients who received Pleurodesis treatment with Sclerosant material.However, still shows symptom. Also patients who had Malignant pleural effusion but haven't response to systemic Chemptherapy or were not candidate to treat by systematic chemotherapy. Also, patients who the clinical and radiological symptoms were stable after one week treatment.
The patient's unwillingness to continue to cooperate, cancers other than lung, breast or mesothelioma, a condition prohibiting the use of cisplatin and kidney and bloodconditions in the patient.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method WBC. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Plt. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Hb. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Cr. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Na. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;K. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Ca. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Mg. Timepoint: Before each injection, each 2 weeks. Method of measurement: Blood test.;Estimation of pleural fluid. Timepoint: Before each injection, each 2 weeks. Method of measurement: Chest X ray.
- Secondary Outcome Measures
Name Time Method Electrolyte Disorder. Timepoint: Each two weeks. Method of measurement: Decrease in Calcium.;Electrolyte disorder. Timepoint: Each two weeks. Method of measurement: Decrease in Magnesium, lower than 1.8 mg/dl.;Electrolyte disorders. Timepoint: Each two weeks. Method of measurement: Decrease of Potassium lower than 5.3 meq/dl.;Bone marrow suppression. Timepoint: Each two weeks. Method of measurement: The bone marrow suppression with drop in WBC to the lower 4000/l or Neutrophils lower than 1500/l or Platelets lower than 100000 or drop in one unit of HB in comparision with post treatment condition.;Shortness of breath. Timepoint: after two weeks. Method of measurement: Borg scale.;Estimation of Pleural effusion. Timepoint: 1 month after injection. Method of measurement: Based onamonth of Pleural fluid.